Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Nesto
Richard W
RW
Bell
David
D
Bonow
Robert O
RO
Fonseca
Vivian
V
Grundy
Scott M
SM
Horton
Edward S
ES
Le Winter
Martin
M
Porte
Daniel
D
Semenkovich
Clay F
CF
Smith
Sidney
S
Young
Lawrence H
LH
Kahn
Richard
R
D001810:Blood Volume / Q000187:drug effects; D002986:Clinical Trials as Topic; D015897:Comorbidity; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced* / Q000503:physiopathology; D005905:Glyburide / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D012449:Safety; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D008687:Metformin; D005905:Glyburide